期刊
KIDNEY INTERNATIONAL
卷 91, 期 3, 页码 539-551出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.10.005
关键词
anti-complement therapies; atypical hemolytic uremic syndrome; C3 glomerulopathy; complement; glomerulonephritis; kidney disease
资金
- Akari Therapeutics
- Alexion
- Achillion
- Fight for Sight
- Kidney Research UK
- Macular Society
- Medical Research Council
- Northern Counties Kidney Research Fund
- Wellcome Trust
- Novartis
- CSL Behring
- Kidney Disease: Improving Global Outcomes (KDIGO)
- Achillion Pharmaceuticals
- Alexion Pharmaceuticals
- Omeros
- Academy of Medical Sciences (AMS) [AMS-SGCL5-Gale] Funding Source: researchfish
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据